Loading articles...
MASH (metabolic dysfunction-associated steatohepatitis) is a complex disease, and while we've made strides, key mechanistic details remain elusive. This demands a sharper focus on translational studies that can directly inform clinical practice.
Pulmonary embolism, while often linked to deep vein thrombosis, can arise from unexpected sources. This case highlights the need for clinicians to consider rare etiologies in unexplained PE.
Patients on lorlatinib require vigilant monitoring for hyperglycemia and ketoacidosis, regardless of pre-existing diabetes risk factors. Proactive screening and early intervention are crucial to mitigate potential severe complications and ensure patient saf...
Patients on lorlatinib may develop diabetes with unusual characteristics, including the absence of typical autoantibodies. This presents a diagnostic challenge, requiring clinicians to consider drug-induced etiologies even when initial immunological markers...
Patients on lorlatinib should be monitored for hyperglycemia, regardless of autoantibody status. This case raises concerns about potential metabolic toxicities of ALK inhibitors beyond what is currently recognized.
A new study investigates the systemic and gut microbiome changes associated with metformin and liraglutide treatment in adolescents with type 2 diabetes. The findings offer potential insights into gastrointestinal side effects and treatment choices.
A recent case report highlights the complexities in diagnosing fatal pulmonary embolism (PE) stemming from unusual causes, emphasizing the need for vigilance and broad diagnostic consideration. The case underscores how delayed recognition of rare cytotoxici...
A new review in Nature Reviews Gastroenterology & Hepatology clarifies the complex interplay of metabolism, inflammation, and fibrosis in metabolic dysfunction-associated steatohepatitis (MASH). This understanding translates to practical guidance for risk s...
Opportunistic osteoporosis screening using cranial CT scans could identify more patients at risk of major osteoporotic fractures. However, widespread implementation faces hurdles including medico-legal considerations and reimbursement complexities.
SGLT2 inhibitors show potential for managing glycemic control in Prader-Willi Syndrome, but clinicians must be vigilant about the risk of renal complications. This necessitates careful patient selection and close monitoring of kidney function throughout tre...